TITLE

SEATTLE GENETICS LICENSES PROACTA'S CELL-KILLING DRUGS

PUB. DATE
December 2001
SOURCE
Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Deals with the licensing of cell-killing drugs from Proacta Therapeutics by Seattle Genetics Inc. Plans of Seattle Genetics for the drugs; Signficance of the agreement to Seattle Genetics; Background on Proacta Therapeutics.
ACCESSION #
7121026

 

Related Articles

  • Seattle Genetics Inks $200M Licensing Deal with Pfizer. Shaffer, Catherine // BioWorld Today;1/7/2011, Vol. 22 Issue 5, p1 

    The article reports on a licensing deal signed by Pfizer Inc. with Seattle Genetics Inc. (Seagen) for access to Seattle's antibody-drug conjugate (ADC). The 200 million dollar deal was reportedly closed at a significant premium over a similar deal with GlaxoSmithKline plc in December 2009. It...

  • Bayer and Seattle Genetics form tumor treatment alliance.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p15 

    Announces that Bayer Pharmaceutical Corp. has licensed anticancer biotechnology firm Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology to fight tumors by linking cell-killing drugs to antibodies. Terms of the agreement; Seattle Genetics' development of improved ADC...

  • Seattle, Genentech extend antibody agreement.  // PharmaWatch: Biotechnology;May2007, Vol. 6 Issue 5, p13 

    The article provides updates on the alliance of Genentech company and Seattle Genetics Inc. in the U.S. According to reports, Genentech has extended its antibody-drug conjugate agreement with Seattle Genetics and will have exclusive licenses to specific targets and use of Seattle's antibody-drug...

  • Seattle Genetics Inks $200M Licensing Deal with Pfizer.  // Bioworld Week;1/10/2011, Vol. 19 Issue 2, p5 

    The article focuses on the 200 million dollars licensing deal with Seattle Genetics Inc. and Pfizer Inc. for the Seagen's antibody-drug conjugate

  • SGI Files for Brentuximab BLA, Eyes 20ll Approval.  // Bioworld Week;3/7/2011, Vol. 19 Issue 10, p3 

    The article reports on the approval of the drug, Brentuximab BLA, developed by Seattle Genetics Inc. of Bothell, Washington.

  • No Sweets for Protein Affects Immunity. Breindl, Anette // BioWorld Today;3/18/2013, Vol. 24 Issue 51, Special section p1 

    The article discusses research on the development of orally active fucosylation inhibitors, conducted by Seattle Genetics Inc. researchers and published in the March 11, 2013 online issue of "Proceedings of the National Academy of Sciences" journal.

  • Other News To Note.  // BioWorld Today;1/17/2012, Vol. 23 Issue 10, p2 

    The article reports on the move of Seattle Genetics Inc. to update its prescribing information for Adcetris.

  • ALZA LICENSES DAPOXETINE FROM PPD GENUPRO.  // Biotech Business;Feb2001, Vol. 14 Issue 2, p1 

    Reports that ALZA Corp. and PPD Inc. have licensed the dapoxetine drug of PPD GenuPro for genitourinary therapies, including premature ejaculation.

  • Clinic Roundup.  // BioWorld Today;1/28/2013, Vol. 24 Issue 18, p8 

    The article reports on the results of the Phase I trial conducted by Seattle Genetics Inc. to its ASG-5ME in metastatic pancreatic ductal adenocarcinoma which identified the maximumtolerated dose for weekly administration of the said drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics